Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 20,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Recruiting Phase 1 Interventional

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

NCT07001384
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Interventions
Alectinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Nov 1, 2026, 1:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

NCT00150098
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Enhanced HIV risk reduction and HIV vaccine education
Behavioral
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Nov 1, 2026, 1:14 AM EST
Completed Not applicable Interventional Results available

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
inhaled/swallowed budesonide, viscous/swallowed budesonide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Nov 1, 2026, 1:14 AM EST
Recruiting Not applicable Interventional

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

NCT06898905
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bridging Radiation Therapy
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Terminated No phase listed Observational

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions
FNA Biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Nov 1, 2026, 1:14 AM EST
Recruiting Not applicable Interventional

NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities

NCT06810622
View directory record Official record
Conditions
Kidney Diseases, Chronic Kidney Diseases
Interventions
Community health worker intervention, Standard Care (in control arm)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Denver, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Timing of Insulin Before Meals Everyday

NCT00789945
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control, Study Arm B
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT00098839
View directory record Official record
Conditions
Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 31 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Glutathione and Function in HIV Patients

NCT02348775
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
GlyNAC (combination of glycine and n-acetylcysteine)
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01472757
View directory record Official record
Conditions
Asthma
Interventions
VR506, Placebo
Drug
Lead sponsor
Vectura Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Nov 1, 2026, 1:14 AM EST
Recruiting Phase 1 Interventional

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

NCT07586618
View directory record Official record
Conditions
Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions
4A10
Drug
Lead sponsor
Allterum Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03349060
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Nov 1, 2026, 1:14 AM EST
Recruiting No phase listed Observational

Expanding HOPE Liver

NCT07778459
View directory record Official record
Conditions
HIV Infection, Liver Transplant
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 1 Interventional

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

NCT03713580
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
Venetoclax
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 3 Interventional Results available

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

NCT01039688
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Disease-modifying antirheumatic drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Nov 1, 2026, 1:14 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens

NCT00001294
View directory record Official record
Conditions
Alcoholism, HIV Infection, Homosexuality, Kaposi's Sarcoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

NCT00793572
View directory record Official record
Conditions
Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 1, 2026, 1:14 AM EST
Completed Phase 3 Interventional Results available

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

NCT02126839
View directory record Official record
Conditions
Asthma
Interventions
Albuterol MDPI, Placebo, ProAir HFA inhaler
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 1, 2026, 1:14 AM EST
Completed Not applicable Interventional Results available

Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

NCT00315939
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Device
Lead sponsor
Boris Kovatchev, PhD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Nov 1, 2026, 1:14 AM EST